Lung Cancer
Endowave is a Galway-based medical device company developing next-generation transbronchial microwave ablation technology to enable targeted, minimally invasive treatment of lung cancer.
2 million
People are diagnosed with primary lung cancer each year worldwide.
1.7 million
People die worldwide of lung cancer each year.
No. 1
Cause of cancer death worldwide.
A Major Global Health Challenge
Lung cancer remains one of the most significant global health challenges. Each year, more than 2.5 million people are diagnosed worldwide, and approximately 1.7 million lives are lost to the disease.
Due to its high mortality rate, lung cancer is currently the leading cause of cancer-related death globally. There is a critical need for new treatments that are more effective and less invasive.
Screening programmes are driving a paradigm shift
Global Screening
Screening programmes are being implemented around the globe
Small Curable Lesions
More patients will
be identified earlier with small
curable lesions.
Less Invasive
This opens the opportunity for less invasive, targeted treatments that will create a new era of treatment
Robotic bronchoscopy
The emergence of robotic assisted bronchoscopy is redefining the treatment pathway for lung cancer patients
These advanced systems guide a robotic catheter through the airways, allowing clinicians to precisely access nodules located deep within the lungs.
Targeted treatment with Microwave Ablation
Endowave has developed an advanced microwave ablation system for the treatment of lung cancer.
The system is delivered to the target site using a robotic bronchoscopy platform.
Once in position, controlled microwave energy is emitted from the catheter tip to ablate and destroy the diseased tissue.
Transbronchial microwave ablation
Endowave has developed the FlexABLATE™ system to enable transbronchial treatment of lung cancer.
The FlexABLATE™ catheter has been optimised for deliver through robotic bronchoscopy platforms to reach all parts of the lungs.
Endowave’s proprietary antenna technology produces controlled and predictable ablation zones that align with tumour geometry.
The FlexAblate system is currently being evaluated in a European clinical study.
Investment Opportunity
Please contact us if you would like to learn more.
Our Partners
Our Origins
Endowave was established in 2018 by Jonathan Bouchier-Hayes, Jimmy Eaton-Evans, and Giuseppe Ruvio.
The company emerged from the BioInnovate Programme at the
University of Galway, which assembles multidisciplinary teams to uncover unmet
clinical needs and translate them into innovative solutions and new ventures.
Early research and development carried out by the founders laid the groundwork
for the Endowave microwave technology.
Headquartered in Galway, Endowave now employs more than 20
people. Its technology is being used to treat patients in an ongoing clinical
study in Europe. The team is currently focused on completing the initial phase
of clinical trials and advancing towards regulatory approval and commercial launch.
Leadership Team
Jonathan Bouchier-Hayes
CEO
Jimmy Eaton-Evans
CTO
Giuseppe Ruvio
CSO
Careers at Endowave
- Galway, Ireland
We currently have no job vacancies
Please check back soon for updates.